Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

May 11, 2022

Rallybio buys Sanofi drug candidate with potential as anemia treatment

PHOTO | Steve Laschever Rallybio’s co-founders (from left to right) are: Dr. Stephen Uden, Jeffrey Fryer and Martin Mackay.
By Liese Klein

New Haven-based Rallybio announced Monday it had acquired a preclinical drug candidate from French pharma giant Sanofi that shows promise in the treatment of severe anemia. 

Rallybio paid Sanofi $3 million in cash upfront, plus additional payments due at developmental and commercial milestones and royalties on net sales.

Sanofi’s KY1066, now known as RLYB331, could help treat patients with severe anemia due to ailments like beta thalassemia and a subset of myelodysplastic syndromes.

The deal bolsters Rallybio’s pipeline, reinforces the company’s existing focus on blood disorders and aligns with its rare-disease mission, according to a company statement. 

CEO Martin Mackay said, “With our strong focus on portfolio expansion, the in-licensing of RLYB331, our first as a public company, marks a pivotal moment for Rallybio.”

“Along with our existing pipeline it provides an additional opportunity to leverage our deep expertise in rare diseases and to identify and accelerate the development of transformative therapies,” Mackay added.

In January, Rallybio launched a Phase 1 clinical trial for a drug candidate designed to fight a rare blood disease in newborns.

Contact Liese Klein at lklein@newhavenbiz.com.


 

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF